haas: sorafenib/sunitinib for unfavorable rcc
Published 9 years ago • 121 plays • Length 2:07Download video MP4
Download video MP3
Similar videos
-
8:11
implications of using adjuvant sorafenib and sunitinib in unfavourable renal carcinoma
-
2:11
dr. haas on adjuvant sorafenib or sunitinib for rcc
-
4:03
adjuvant treatment with sorafenib or sunitinib doesn't improve outcomes in localised renal carcinoma
-
19:55
adjuvant sunitinib for high risk renal cell carcinoma: not ready for prime time
-
3:57
agile trial: frontline axitinib versus sorafenib in metastatic renal cell carcinoma
-
5:09
comparz trial and alternate sunitinib dosing schedule in metastatic renal cell carcinoma
-
2:23
s-trac phase iii trial of sunitinib as adjuvant therapy in high-risk renal cell cancer patients
-
1:24
dr. figlin on sunitinib for patients with rcc
-
1:05
dr. balar on phase iii assure trial results for rcc
-
7:34
frontline sunitinib compared to everolimus in metastatic renal cell carcinoma
-
0:55
selecting patients with renal cell carcinoma for adjuvant sunitinib therapy
-
6:26
current data on rcc therapy: sunitinib dosing, combination therapy and more
-
1:17
for patients: targeted therapy treatment risks | dana-farber cancer institute
-
31:14
current treatment of advanced renal cell carcinoma, christian kollmannsberger, md
-
26:50
management of toxicities related to systemic therapy for metastatic renal cell carcinoma
-
3:49
adjuvant sunitinib for renal cell carcinoma
-
2:13
treating advanced renal-cell carcinoma
-
6:19
current data on rcc therapy: sunitinib dosing, combination therapy and more
-
3:09
should sunitinib still be used in the treatment of metstatic kidney cancer?